Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Andrew McConaghie

Senior Writer

Andrew is a London-based journalist who has been writing about pharma, biotech and healthcare for over 20 years.

He writes on a range of topics, including biopharma R&D and commercial issues, digital healthcare and issues affecting patients and global healthcare systems, especially the UK’s NHS.

Latest From Andrew McConaghie

Cambridge Vision Achieved, AstraZeneca Looks To Realize ‘Pipeline 2’ Ambitions

Having achieved a turnaround in its R&D and commercial fortunes, AstraZeneca’s hopes the opening of a new research center will herald its next wave of novel therapies.

Companies Commercial

Gilead Trial Pause Adds To Merck & Co’s HIV Concerns

The partners are halting recruitment out of “an abundance of caution,” but Gilead could decide to exit the alliance if islatravir cannot shake off safety concerns.

Infectious Diseases Companies

Nearly Nine Years In The Making, AstraZeneca Finally Unveils New Cambridge R&D Hub

After an expensive and protracted construction, AstraZeneca hopes its Cambridge research center will help foster collaboration and extend its run of R&D success.

Companies Innovation

Safety Concerns Halt Merck & Co’s Once-Weekly HIV Combination

Merck & Co. is looking to compete in the burgeoning long-acting HIV market, but a safety halt to a Phase II trial could disrupt those plans.

Clinical Trials Companies

Plans For US Government To Negotiate Prices Not A Done Deal, Says AZ’s Dobber

While Democrat politicians - and most voters- want to see drug pricing negotiations introduced in the US for the first time, pharma leaders believe a deal on out of pocket costs will be agreed instead.

Commercial Companies

Pharma Still Hoping To Block US Medicare Price-Setting Legislation

While Democratic politicians – and most voters – want to see drug pricing negotiations introduced in the US for the first time, pharma leaders still believe a deal on out of pocket costs will be agreed instead.

Pricing Debate Legislation
See All
UsernamePublicRestriction

Register